257 related articles for article (PubMed ID: 25796193)
1. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
4. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
[TBL] [Abstract][Full Text] [Related]
5. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
[TBL] [Abstract][Full Text] [Related]
9. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
10. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
11. Graphene oxide polarizes iNKT cells for production of TGFβ and attenuates inflammation in an iNKT cell-mediated sepsis model.
Lee SW; Park HJ; Van Kaer L; Hong S; Hong S
Sci Rep; 2018 Jul; 8(1):10081. PubMed ID: 29973666
[TBL] [Abstract][Full Text] [Related]
12. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
13. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
14. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
15. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
16. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
17. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
18. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
19. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
20. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
